Skip to content
Frontier Desk

LifeMD borrowed $12.5 million secured by its assets and issued warrants to its lenders

LifeMD reported $44.6 million in third-quarter revenue and, after the quarter closed, replaced its credit facility with a $12.5 million senior secured term loan from Avenue Venture Opportunities Fund II and Avenue Growth Lending Fund III. The loan is secured by substantially all of the borrower's assets, and the lenders received warrants to buy $625,000 of LifeMD common stock at the lower of $2.32 per share or the effective price of any equity raise before June 30, 2027.

The idea. A buyer can pay for a company with cash, with its own shares, with payments that depend on later results, or with a mix. Each form moves risk differently: cash at closing settles that part of the price, shares tie part of it to the buyer's future, and payments tied to later results keep the owner exposed to the business after the sale.

LifeMD, a telehealth and pharmacy services company, entered the loan agreement on November 9, 2026, and disclosed it in an 8-K filed November 12 sec.gov. The company had exited the third quarter with $21.9 million of cash and no debt, then took on $12.5 million in secured debt plus warrants. The warrants give the lenders the right to buy shares at a fixed price, which means the lenders share in any upside if LifeMD's stock rises above $2.32 before June 30, 2027. The loan is secured by a first claim on the borrower's assets, so if the company cannot repay, the lenders can take the collateral before any unsecured creditor.

An owner looking at this deal sees three forms of consideration in one transaction. Cash: the $12.5 million loan proceeds. A secured claim: the lenders' right to seize assets if the loan is not repaid. An equity kicker: the warrants, which are a form of contingent payment tied to the company's stock price. The warrants are the piece that looks most like an earn-out in a sale: the borrower gives the lender a share of future value in exchange for better terms today. LifeMD's press release sec.gov said the company entered arrangements with Novo Nordisk and Eli Lilly, and its pharmacy shipment volume grew 58.3% year-over-year. A lender weighing this loan would consider whether the revenue growth and the GLP-1 pharmacy relationships justify the risk of a secured loan to a company that was still losing money on an adjusted EBITDA basis.

What this event shows about how lenders treat firms where software is taking on more of the work is that the lenders demanded both security and upside. LifeMD is a services company that operates telehealth platforms and a pharmacy where software handles patient intake, prescribing and fulfillment. The lenders did not lend on an unsecured basis against the company's cash flow alone. They took a security interest in substantially all assets and they took warrants, which means they wanted a return that goes beyond interest. For an owner of a services company where software is doing more of the work, the lesson is that a lender who understands the business may still ask for collateral and a piece of the equity, especially when the company is not yet profitable on an adjusted basis.

An owner whose company is raising debt or selling should be ready to answer: What assets can you pledge? If the lender asks for warrants, what strike price and what expiration are you willing to accept? How does the lender's secured position affect your ability to borrow from other sources later? And if the loan includes a variable-price warrant tied to a future equity raise, what happens to your own dilution if the company raises capital before the warrant expires?

What to watch next is whether LifeMD's revenue growth and its GLP-1 pharmacy partnerships produce positive adjusted EBITDA in the fourth quarter, and whether the company raises equity before June 30, 2027, which would set the warrant strike price.

  1. LifeMD, Inc. 8-K, 12 November 2026
  2. LifeMD, Inc. press release

LifeMD borrowed $12.5 million secured by its assets and issued warrants to its lenders

LifeMD reported $44.6 million in third-quarter revenue and, after the quarter closed, replaced its credit facility with a $12.5 million senior secured term loan from Avenue Venture Opportunities Fund II and Avenue Growth Lending Fund III.

An owner looking at this deal sees three forms of consideration in one transaction.

The loan
The loan is secured by substantially all of the borrower's assets, and the lenders received warrants to buy $625,000 of LifeMD common stock at the lower of $2.32 per share or the effective price of any equity raise before June 30, 2027.
What to ask
An owner whose company is raising debt or selling should be ready to answer: What assets can you pledge?

Source: LifeMD, Inc. 8-K, 12 November 2026LifeMD, Inc. press release

All notes